MAP3K13

Mitogen-activated protein kinase kinase kinase 13

15,223 patent compounds predicted against MAP3K13, 13,328 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL147331	0.91	2/20
SCHEMBL141930	0.90	2/20
SCHEMBL142206	0.85	2/20
SCHEMBL144842	0.80	2/20
SCHEMBL144192	0.75	2/20
SCHEMBL144525	0.71	2/20
SCHEMBL146263	0.71	2/20
SCHEMBL141676	0.69	2/20
SCHEMBL145500	0.69	2/20
SCHEMBL144281	0.68	2/20
SCHEMBL141372	0.68	2/20
SCHEMBL145902	0.67	2/20
SCHEMBL146743	0.67	2/20
SCHEMBL144785	0.67	2/20
SCHEMBL147096	0.63	2/20
SCHEMBL144209	0.62	2/20
SCHEMBL144321	0.61	2/20
SCHEMBL146728	0.61	2/20
SCHEMBL147975	0.60	2/20
SCHEMBL144930	0.60	2/20

Germline variants in MAP3K13 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MAP3K13 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MAP3K13 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	PHASE1/PHASE2	RECRUITING
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	PHASE2	RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
MEK162 for Patients With RAS/RAF/MEK Activated Tumors	PHASE2	COMPLETED
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	PHASE2	UNKNOWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment	nan	ACTIVE_NOT_RECRUITING
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING
RASopathy Biorepository	nan	RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAP3K13 binder may also engage these)

Protein	Name	Similarity
A7MBB4	—	1.000	A7MBB4 →
Q5R8X7	—	1.000	Q5R8X7 →
Q1HKZ5	—	1.000	Q1HKZ5 →
A7J1T2	—	1.000	A7J1T2 →
Q63553	—	1.000	Q63553 →
O14490	—	1.000	O14490 →
Q499D0	—	1.000	Q499D0 →
Q9D415	—	1.000	Q9D415 →
B1AZP2	—	1.000	B1AZP2 →
A7J1T0	—	1.000	A7J1T0 →
O01700	—	0.999	O01700 →
P22199	—	0.999	P22199 →
Q86TC9	—	0.999	Q86TC9 →
Q811P8	—	0.999	Q811P8 →
Q8BJ42	—	0.999	Q8BJ42 →
Q8C0I4	—	0.999	Q8C0I4 →
Q17QK1	—	0.999	Q17QK1 →
KMT5B	Histone-lysine N-methyltransferase KMT5B	0.999	landscape →
SNRK	SNF-related serine/threonine-protein kinase	0.999	landscape →
Q5SW75	—	0.998	Q5SW75 →
O35607	—	0.998	O35607 →
A2A3K4	—	0.998	A2A3K4 →
Q6AXJ7	—	0.998	Q6AXJ7 →
Q2PFD7	—	0.998	Q2PFD7 →
Q60610	—	0.998	Q60610 →
Q2NKQ1	—	0.998	Q2NKQ1 →
Q6NTJ3	—	0.998	Q6NTJ3 →
Q71QF9	—	0.998	Q71QF9 →
P10244	—	0.998	P10244 →
A6NIR3	—	0.998	A6NIR3 →